Page last updated: 2024-10-25

clofibric acid and HIV-Associated Lipodystrophy Syndrome

clofibric acid has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies

Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.

HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.

Research Excerpts

ExcerptRelevanceReference
" Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited."4.82Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davidson, MH1

Reviews

1 review available for clofibric acid and HIV-Associated Lipodystrophy Syndrome

ArticleYear
Management of dyslipidemia in patients with complicated metabolic syndrome.
    The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A

    Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co

2005